NO20092306L - Forbindelser og fremgangsmater for interaksjoner av BCL proteiner med binding partnere - Google Patents
Forbindelser og fremgangsmater for interaksjoner av BCL proteiner med binding partnereInfo
- Publication number
- NO20092306L NO20092306L NO20092306A NO20092306A NO20092306L NO 20092306 L NO20092306 L NO 20092306L NO 20092306 A NO20092306 A NO 20092306A NO 20092306 A NO20092306 A NO 20092306A NO 20092306 L NO20092306 L NO 20092306L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- interactions
- methods
- binding partners
- bcl proteins
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/600,332 US7842815B2 (en) | 2004-06-17 | 2006-11-15 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| PCT/US2007/023941 WO2008060569A1 (en) | 2006-11-15 | 2007-11-14 | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20092306L true NO20092306L (no) | 2009-08-17 |
Family
ID=39064388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20092306A NO20092306L (no) | 2006-11-15 | 2009-06-15 | Forbindelser og fremgangsmater for interaksjoner av BCL proteiner med binding partnere |
Country Status (20)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2677045C (en) | 2007-01-31 | 2016-10-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| CA2682174C (en) | 2007-03-28 | 2021-04-06 | President And Fellows Of Harvard College | Stitched polypeptides |
| CN104474529A (zh) * | 2008-02-08 | 2015-04-01 | 爱勒让治疗公司 | 治疗性的拟肽大环化合物 |
| US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
| US8945853B2 (en) | 2012-02-06 | 2015-02-03 | Discoverx Corporation | Detection of intracellular binding events by measuring protein abundance |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| CN112500466B (zh) | 2012-02-15 | 2022-05-03 | 艾瑞朗医疗公司 | 拟肽大环化合物 |
| CN103656642A (zh) * | 2012-08-31 | 2014-03-26 | 中国科学院上海生命科学研究院 | 预防和治疗结直肠癌的方法和试剂 |
| WO2014078014A2 (en) | 2012-11-14 | 2014-05-22 | Metabolix, Inc. | Production of salts of 4-hydroxybutyrate using biobased raw materials |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| RU2716256C2 (ru) | 2014-01-28 | 2020-03-11 | Бак Инститьют Фо Ресеч Он Эйджинг | Способы и композиции для уничтожения стареющих клеток и для лечения заболеваний и расстройств, ассоциированных со старением |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP3197478A4 (en) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| CN108368161A (zh) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | 作为mcl-1调节剂的拟肽大环化合物 |
| NZ747404A (en) | 2016-03-28 | 2020-03-27 | Presage Biosciences Inc | Pharmaceutical combinations for the treatment of cancer |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| ES2931533T3 (es) * | 2017-04-05 | 2022-12-30 | Harvard College | Compuesto macrocíclico y usos del mismo |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN113453679B (zh) | 2018-12-20 | 2025-07-08 | C4医药公司 | 靶向蛋白降解 |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| US20230270816A1 (en) | 2020-07-06 | 2023-08-31 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS55133364A (en) | 1979-04-03 | 1980-10-17 | Mitsubishi Petrochem Co Ltd | Preparation of isoxazolidine derivative |
| DE3643012A1 (de) | 1986-12-17 | 1988-06-30 | Hoechst Ag | 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| US5494911A (en) | 1990-05-18 | 1996-02-27 | Hoechst Aktiengesellschaft | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use |
| US5294617A (en) * | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| DK0623615T3 (da) * | 1993-05-01 | 1999-12-13 | Merck Patent Gmbh | Adhæsionsreceptor-antagonister |
| WO1995014683A1 (en) | 1993-11-24 | 1995-06-01 | The Du Pont Merck Pharmaceutical Company | Novel isoxazoline and isoxazole fibrinogen receptor antagonists |
| ATE169009T1 (de) | 1994-03-09 | 1998-08-15 | Pfizer | Isoxazoline verbindung zur hemmung tnf-freigabe |
| US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| DE19539638A1 (de) | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
| US6221865B1 (en) * | 1995-11-06 | 2001-04-24 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| JP2000516234A (ja) | 1996-08-16 | 2000-12-05 | デュポン ファーマシューティカルズ カンパニー | アミジノフェニル―ピロリジン類、アミジノフェニル―ピロリン類、およびアミジノフェニル―イソオキサゾリジン類およびそれらの誘導体 |
| WO1998016830A2 (en) | 1996-10-16 | 1998-04-23 | The President And Fellows Of Harvard College | Droplet assay system |
| PH11998001073B1 (en) | 1997-05-07 | 2007-07-23 | Univ Pittsburgh | Inhibitors of protein isoprenyl transferases |
| WO2001016115A1 (en) | 1999-09-01 | 2001-03-08 | Chemrx Advanced Technologies, Inc. | Process for synthesizing isoxazolidines |
| KR100399361B1 (ko) * | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
| ATE474568T1 (de) | 2001-05-30 | 2010-08-15 | Univ Michigan | Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs. |
| FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
| AU2005265131B2 (en) | 2004-06-17 | 2012-02-23 | Infinity Discovery, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| WO2006009907A2 (en) * | 2004-06-17 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Isoxazolidine compounds for treatment of bacterial infections |
| TWI403320B (zh) * | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法 |
-
2006
- 2006-11-15 US US11/600,332 patent/US7842815B2/en not_active Expired - Fee Related
-
2007
- 2007-11-14 EP EP07840052.0A patent/EP2094673B1/en active Active
- 2007-11-14 BR BRPI0718606-1A patent/BRPI0718606A2/pt not_active IP Right Cessation
- 2007-11-14 CN CN200780049702.7A patent/CN101583606B/zh not_active Expired - Fee Related
- 2007-11-14 RU RU2009121808/04A patent/RU2449996C2/ru not_active IP Right Cessation
- 2007-11-14 WO PCT/US2007/023941 patent/WO2008060569A1/en not_active Ceased
- 2007-11-14 JP JP2009537198A patent/JP2010510214A/ja active Pending
- 2007-11-14 NZ NZ577243A patent/NZ577243A/en not_active IP Right Cessation
- 2007-11-14 AU AU2007319848A patent/AU2007319848B2/en not_active Ceased
- 2007-11-14 ES ES07840052.0T patent/ES2537762T3/es active Active
- 2007-11-14 CA CA2669596A patent/CA2669596C/en not_active Expired - Fee Related
- 2007-11-14 KR KR1020097012239A patent/KR101530721B1/ko not_active Expired - Fee Related
- 2007-11-14 MY MYPI20091840A patent/MY156754A/en unknown
- 2007-11-14 MX MX2009005184A patent/MX2009005184A/es active IP Right Grant
-
2009
- 2009-05-06 IL IL198597A patent/IL198597A/en not_active IP Right Cessation
- 2009-05-08 TN TNP2009000182A patent/TN2009000182A1/fr unknown
- 2009-05-12 GT GT200900123A patent/GT200900123A/es unknown
- 2009-06-09 EC EC2009009398A patent/ECSP099398A/es unknown
- 2009-06-10 MA MA31972A patent/MA31067B1/fr unknown
- 2009-06-15 NO NO20092306A patent/NO20092306L/no not_active Application Discontinuation
-
2010
- 2010-11-30 US US12/956,969 patent/US8461191B2/en not_active Expired - Fee Related
-
2013
- 2013-11-07 JP JP2013230960A patent/JP2014055156A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20110160259A1 (en) | 2011-06-30 |
| US8461191B2 (en) | 2013-06-11 |
| IL198597A (en) | 2014-03-31 |
| BRPI0718606A2 (pt) | 2013-12-17 |
| IL198597A0 (en) | 2010-02-17 |
| HK1130057A1 (en) | 2009-12-18 |
| MX2009005184A (es) | 2009-10-12 |
| US7842815B2 (en) | 2010-11-30 |
| KR101530721B1 (ko) | 2015-06-22 |
| WO2008060569A1 (en) | 2008-05-22 |
| CN101583606A (zh) | 2009-11-18 |
| AU2007319848B2 (en) | 2012-05-03 |
| GT200900123A (es) | 2011-09-02 |
| CA2669596C (en) | 2014-09-30 |
| MY156754A (en) | 2016-03-31 |
| NZ577243A (en) | 2011-12-22 |
| RU2009121808A (ru) | 2010-12-20 |
| ES2537762T3 (es) | 2015-06-11 |
| JP2010510214A (ja) | 2010-04-02 |
| CN101583606B (zh) | 2015-04-08 |
| US20080306127A9 (en) | 2008-12-11 |
| JP2014055156A (ja) | 2014-03-27 |
| US20070161690A1 (en) | 2007-07-12 |
| EP2094673A1 (en) | 2009-09-02 |
| AU2007319848A1 (en) | 2008-05-22 |
| CA2669596A1 (en) | 2008-05-22 |
| RU2449996C2 (ru) | 2012-05-10 |
| KR20090082284A (ko) | 2009-07-29 |
| ECSP099398A (es) | 2009-07-31 |
| TN2009000182A1 (en) | 2010-10-18 |
| EP2094673B1 (en) | 2015-04-08 |
| MA31067B1 (fr) | 2010-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20092306L (no) | Forbindelser og fremgangsmater for interaksjoner av BCL proteiner med binding partnere | |
| NO20091213L (no) | Forbindelser og fremgangsmater for a inhibere interaksjoner mellom BCL proteiner og bindingspartnere | |
| NO20070324L (no) | Forbindelser og fremgangsmater for inhibering av BCL proteiner med bindingspartnere | |
| NO20083050L (no) | Forbindelser og fremgangsmater for hemming av interaksjon av Bcl-proteiner med bindingspartnere | |
| NO20092652L (no) | Konstruert anti-TSLP-antistoff | |
| EA201000717A1 (ru) | Молекулы и способы, предназначенные для модуляции компонента системы комплемента | |
| NO20090624L (no) | Forbindelser som modulerer CB2 receptoren | |
| EA200970737A1 (ru) | Оксабициклогептаны и оксабициклогептены, их получение и применение | |
| TW200640924A (en) | VEGF-R2 inhibitors and methods | |
| EA200602179A1 (ru) | Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств | |
| EA201790678A1 (ru) | Бициклические гетероарильные соединения | |
| EA200901119A1 (ru) | АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ | |
| EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
| EA200702363A1 (ru) | Новые лиганды гистамина h-рецептора и их терапевтические применения | |
| EA201000391A1 (ru) | Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция | |
| EA201000392A1 (ru) | Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция | |
| EA200801413A1 (ru) | Гетероциклические сетр ингибиторы | |
| WO2007022947A3 (de) | 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren | |
| ATE417849T1 (de) | Pyrazoloä4,3-düpyrimidine | |
| DE602006020585D1 (de) | Neue cysteinproteasehemmer und ihre therapeutische anwendung | |
| MY155908A (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| TNSN06418A1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| EA200702590A1 (ru) | Ингибиторы растворимой аденилатциклазы | |
| EA200900574A1 (ru) | Солевые формы замещённых бензотиенильных соединений | |
| NO20065800L (no) | IL-13 bindingsmidler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |